1.5 minute read
In 2021, prescription drug spending by private health plans nearly reached $152 billion, an 18% increase since 2016. Some researchers and stakeholders are scrutinizing certain Pharmacy Benefit Managers’ (PBMs) practices, such as keeping rebates and engaging in spread pricing. All 50 states have passed at least one law concerning PBMs from 2017-2023.
The U.S. Government Accountability Office (GAO) has recently submitted a report to Congress that sheds light on the actions taken by state authorities in Arkansas, California, Louisiana, Maine, and New York. The report offers guidance for PBMs, insurers, and plan sponsors navigating compliance obligations in this evolving legal landscape.
Private health plans contract with PBMs to manage prescription drug benefits, including claims processing, network development, and rebate negotiations with drug manufacturers. With minimal federal regulation, states are enacting laws to regulate PBMs, prompting GAO to review state regulations.
The GAO found these common themes from these states’ PBM laws.
In addition, regulators have expressed that broad regulatory authority is more effective than specific statutory provisions, emphasizing the importance of robust enforcement of PBM laws. Plan sponsors in all states to keep abreast of state regulations concerning PBMs, as this legal domain is rapidly evolving and the oversight of PBMs is increasingly prioritized. Download the bulletin for more details.